Saxagliptin Hydrochloride/Metformin Hydrochloride

盐酸沙格列汀/盐酸二甲双胍

Report date: 2023/04/25 11:29:54

Base Information

Drug NameSaxagliptin Hydrochloride/Metformin Hydrochloride
Drug Alias Name沙格列汀水合物/盐酸二甲双胍Saxagliptin/Metformin HydrochlorideSaxagliptin Hydrate•Metformin Hydrochloride沙格列汀和盐酸二甲双胍沙格列汀•盐酸二甲双胍 +[14] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2010/11/05
Country/TerritoryUnited StatesPuerto RicoHungary +[6] 
CombinationsYes Metformin HydrochlorideSaxagliptin Hydrate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Ab
Inactive CompaniesAstrazeneca Plc
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD10
Related LinksKEGG